2004N-0330 - Joint Meeting of the Psychopharmacologic Drugs Advisory Committee and the Pediatric Advisory Committee
FDA Comment Number : EC20
Submitter : Dr. David Healy Date & Time: 09/03/2004 06:09:45
Organization : Cardiff University
Health Professional
Category :
Issue Areas/Comments
At some point in the past few weeks, Pfizer posted on the FDA website material purportedly relevant to the PDAC hearing on antidepressants in pediatric trials, scheduled for September 13th/14th. This material contained a sustained ad hominem attack on me, much of which is manifestly false, raising questions as the motives for posting such material. The material was apparently vetted before posting by FDA's chief counsel, Daniel Troy, who has formerly worked closely with Pfizer. The attached documents offer a preliminary response.